- $120.95m
- $107.23m
- $2.04m
Humacyte Inc expected to post a loss of 22 cents a share - Earnings Preview
Humacyte Inc reports results for the quarter ended in December - Earnings Summary
Brief: Humacyte Q4 Basic EPS USD -0.24
Humacyte Inc expected to post a loss of 24 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Madrigal Pharma, Copper miners, NetApp
U.S. STOCKS ON THE MOVE-Cooper, US energy stocks, Vista Outdoor
U.S. STOCKS ON THE MOVE-Old Republic, TDCX, Repay Holdings
Humacyte tumbles as stock offering priced at steep discount
Brief: Humacyte, Inc. Announces Pricing Of $40.2 Million Public Offering Of Common Stock
Brief: Humacyte Announces Proposed Public Offering Of Common Stock
U.S. STOCKS ON THE MOVE-New York Community Bancorp, Ralph Lauren, Newell Brands
U.S. STOCKS ON THE MOVE-Take-Two Interactive, PepsiCo, Moderna
Humacyte gains after US FDA grants priority review for blood vessel replacement implant
U.S. RESEARCH ROUNDUP-Expedia Group, Meta Platforms, Rayzebio
Brief: Humacyte Submits Biologics License Application To US FDA Seeking Approval Of Human Acellular Vessel For The Treatment Of Vascular Trauma
Humacyte up on positive trial data for bio-engineered human tissue
Brief: Humacyte Announces Two Presentations Of Positive Clinical Results Of The Human Acellular Vessel
Brief: Humacyte Q3 Basic EPS USD -0.25
U.S. RESEARCH ROUNDUP-Dollar Tree, Hexcel, Humacyte